A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

The FDA has released a statement saying it will “carefully shepherd” studies to advance the development of chimeric antigen ...

Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...

Allogene Therapeutics’ gamble on a never-before-seen trial strategy seems to be paying off, with the biotech’s off-the-shelf cell therapy eradicating residual lymphoma in over half of evaluated pat | ...

The latest chemistry news, including important research advances, business and policy trends, chemical safety practices, career guidance, and more. Current approved CAR T-cell therapy treatments rely ...

Cancers that were once considered incurable now have new treatment options. Among these innovations are CAR-T (chimeric ...

In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...

A protein that helps cancer cells hide from the immune system may have a critical weakness, according to research that could ...

The new data bolster Allogene’s efforts to develop a new, easily administered cell therapy that could delay or prevent cancer recurrence.

Scientists have discovered how two transcription factors form a reciprocal regulatory circuit that controls T-cell exhaustion ...